Loading...

CartiHeal’s Agili-C™ Implant Promotes the Regenerative Capacity of Articular Cartilage Defects in Human Cadaveric Ex-vivo Model

KFAR SABA, Israel, Nov. 6, 2018 /PRNewswire/ -- CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of joint surface lesions, announced today the publication of a study demonstrating that the Agili-C™ implant promotes the regenerative capacity of articular cartilage defects in human cadaveric ex-vivo model. The study, published in KSSTA Journal - Knee Surgery, Sports Traumatology, Arthroscopy (01 November 2018, PP

By |2018-11-06T22:46:26+00:00November 6th, 2018|Extremities|
Read More

Mazor Robotics Reports Third Quarter and Nine Month 2018 Results

CAESAREA, Israel, Nov. 6, 2018 /PRNewswire/ -- Mazor Robotics Ltd. (TASE: MZOR) (NASDAQGM: MZOR), a pioneer and a leader in the field of robotic guidance systems, reported financial and operating results for the third quarter and nine months ended September 30, 2018. As announced on September 20, 2018, the Company entered into a definitive merger agreement under which Medtronic

By |2018-11-06T22:22:33+00:00November 6th, 2018|Financial|
Read More

Medicrea to Attend the 9th Annual Craig-Hallum Alpha Select Conference

November 05, 2018 LYON & NEW YORK--(BUSINESS WIRE)--The Medicrea Group (Euronext Growth Paris: FR0004178572-ALMED ; OTCQX Best Market – MRNTY & MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling and patient specific implants with its UNiD™ ASI (Adaptive Spine Intelligence) proprietary software platform, services and technologies, announced today that the company

By |2018-11-06T19:00:44+00:00November 6th, 2018|Spine|
Read More

MiMedx To Present Clinical And Scientific Studies At Desert Foot Conference

MARIETTA, Ga., Nov. 6, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that five poster abstracts reporting on the Company's EpiFix® dehydrated Human Amnion/Chorion Membrane (dHACM) allograft and EpiCord® dehydrated human umbilical cord (dHUC) allograft will be presented at the Desert Foot 15th Annual Multi-Disciplinary Limb Salvage Conference

By |2018-11-06T18:04:22+00:00November 6th, 2018|Biologics|
Read More

Rapid Company Growth Prompts joimax® Inc. to Move Its US Headquarters to a New, Larger State-of-the-Art Facility

November 05, 2018 IRVINE, Calif.--(BUSINESS WIRE)--joimax®, the Germany-based market leader of technologies and training methods for full-endoscopic minimally invasive spinal surgery, announces the move of its US headquarters to a new 26,000-square-foot facility in Irvine, California, beginning November 5, 2018. “With the move to the new building, the steadily growing need for endoscopic procedures among patients

By |2018-11-05T20:35:19+00:00November 5th, 2018|Spine, Top Stories|
Read More

EOS imaging Leadership Transition to Strengthen U.S. Strategy

November 05, 2018 PARIS--(BUSINESS WIRE)--Regulatory News: EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), the pioneer of orthopedic medical imaging 2D / 3D, announces the change of its leadership effective January 1, 2019. The Board of Directors, in agreement with Marie Meynadier, Chief Executive Officer of EOS imaging, has decided to change

By |2018-11-05T17:48:45+00:00November 5th, 2018|Extremities|
Read More

Shoulder Innovations Announces FDA 510(k) Clearance For Shoulder Technology

HOLLAND, Mich., Nov. 5, 2018 /PRNewswire/ -- Shoulder Innovations announced today that they have received FDA clearance for their InSet Humeral Short Stem System.  This is a key addition to their expanding shoulder portfolio and another milestone for their vision to offer a complete leading technology shoulder arthroplasty product line. The clearance covers products used for partial or total shoulder arthroplasty

By |2018-11-05T16:30:20+00:00November 5th, 2018|Regulatory|
Read More

Conformis Reports Third Quarter 2018 Financial Results and Updates Fiscal Year 2018 Guidance

BILLERICA, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell patient specific joint replacement implants designed to fit each patient's unique anatomy, announced today financial results for the third quarter ended September 30, 2018. Q3 Summary Total revenue

By |2018-11-02T19:33:17+00:00November 2nd, 2018|Financial|
Read More

OsteoRemedies® Announces the First FDA Cleared Dual-Antibiotic Spacer and Bone Cement with Gentamicin and Vancomycin

MEMPHIS, Tenn., Nov. 1, 2018 /PRNewswire/ -- OsteoRemedies®, LLC, a company focused on providing simple solutions to complex disorders, is pleased to announce the launch of the REMEDY SPECTRUM™️ GV Hip Spacer System and SPECTRUM™️ GV Bone Cement.  Building on its portfolio consisting of the only pre-made modular spacer system with Gentamicin for Hip, Knee and Shoulders, the REMEDY

By |2018-11-02T15:43:56+00:00November 2nd, 2018|Recon|
Read More

Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway

WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today provided an update on the NeoCart regulatory pathway based on preliminary feedback from the Type C meeting held with the U.S. Food and

By |2018-11-01T22:04:05+00:00November 1st, 2018|Biologics, Regulatory|
Read More
Odysseus Medical Solutions 2018
RssEmail